How India Exports Metoclopramide to the World

Metoclopramide has been a staple in the U.S. pharmaceutical market for several decades, with numerous Abbreviated New Drug Applications (ANDAs) approved by the FDA. A notable approval includes UDL Laboratories, Inc.'s metoclopramide oral solution (ANDA 75-051) on January 26, 2001. More recently, on September 4, 2009, Wilmington Pharmaceuticals received approval for Metozolv ODT (metoclopramide hydrochloride) orally disintegrating tablets (NDA 022246). Additionally, on September 16, 2009, ANI Pharmaceuticals Inc. obtained approval for metoclopramide oral solution USP, 5 mg/5 mL (ANDA 71-402/S-008).

The regulatory pathway for metoclopramide in the U.S. involves the submission of an ANDA, demonstrating bioequivalence to the reference listed drug. Given the established market presence and multiple approvals, Indian exporters aiming to enter the U.S. market must ensure strict compliance with FDA regulations, including adherence to current Good Manufacturing Practices (cGMP) and thorough documentation of bioequivalence studies. The presence of 321 active Indian exporters underscores the competitive landscape, necessitating a robust regulatory strategy for market entry.

In the European Union, metoclopramide-containing medicines have been subject to regulatory scrutiny to ensure patient safety. In October 2013, the European Medicines Agency (EMA) recommended changes to the use of metoclopramide, including restricting the dose and duration to minimize the risk of neurological side effects. (ema.europa.eu) These recommendations were confirmed in December 2013. (ema.europa.eu) Manufacturers must comply with EU Good Manufacturing Practice (GMP) guidelines, which encompass quality management, personnel, premises, equipment, documentation, production, quality control, and self-inspection. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the marketing authorization of medicinal products, ensuring they meet safety, quality, and efficacy standards.

Metoclopramide is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in a basic health system. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and formulation across different regions.

In India, metoclopramide is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription drug and should be dispensed only on the prescription of a registered medical practitioner. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of the latest available data, metoclopramide is not listed under the Drugs (Prices Control) Order (DPCO), implying no ceiling price is currently imposed. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations.

Metoclopramide's primary patents have long expired, leading to a competitive generic market. This expiration has facilitated the entry of multiple generic manufacturers, including Indian exporters, into both domestic and international markets.

In December 2025, the European Medicines Agency (EMA) recommended updates to the product information for metoclopramide-containing medicines to include visual disturbances and oculogyric crisis as potential adverse effects. (ema.europa.eu) This underscores the importance of continuous pharmacovigilance and the need for manufacturers to update safety information accordingly.

In January 2026, the U.S. FDA issued a tentative approval for Teva Pharmaceuticals' metoclopramide nasal spray (ANDA 216931), indicating that the product meets the necessary requirements but cannot be marketed until patent or exclusivity issues are resolved. This development highlights ongoing innovation in drug delivery methods for metoclopramide.

These developments reflect the dynamic regulatory environment surrounding metoclopramide, emphasizing the need for exporters to stay informed and compliant with evolving standards and requirements.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs), the essential chemical precursors for Active Pharmaceutical Ingredients (APIs). Approximately 41% of KSMs used in U.S.-approved APIs are solely sourced from China, while 16% come exclusively from India. This dependency poses significant risks, as any disruption in China's supply chain can directly impact India's API production capabilities.

Recent events have highlighted this vulnerability. In February 2026, the closure of the Strait of Hormuz due to geopolitical tensions led to a sharp decline in maritime transit, affecting global energy supplies and causing oil prices to surge. Such disruptions can have cascading effects on the availability and cost of raw materials necessary for API production.

The export market for Metoclopramide from India is notably concentrated. The top five exporters account for 72.9% of the total export value, with IPCA Laboratories Limited alone contributing 48.1% ($10.9 million USD). This high concentration increases the risk of supply chain disruptions if any of these key suppliers face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic production of critical APIs and reduce reliance on imports. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, marking a significant step towards self-sufficiency.

Geopolitical tensions have recently escalated, notably with the 2026 Strait of Hormuz crisis, where military actions led to the effective halt of shipping traffic through this critical passage. This disruption affected about 20% of the world's daily oil supply and significant volumes of liquefied natural gas (LNG), causing major shipping firms to suspend operations in the area.

Additionally, the Red Sea has experienced increased instability due to regional conflicts, leading to rerouted shipping lanes and extended transit times. Such disruptions can delay the delivery of essential raw materials and finished pharmaceutical products, impacting global supply chains.

• Diversify Supplier Base: Encourage the development of alternative suppliers for KSMs and APIs to reduce dependency on a single country or supplier.

• Enhance Domestic Production: Continue to invest in domestic manufacturing capabilities through initiatives like the PLI scheme to achieve self-sufficiency in critical pharmaceutical ingredients.

• Strengthen Supply Chain Resilience: Develop contingency plans and maintain strategic reserves of essential raw materials to buffer against geopolitical and logistical disruptions.

• Monitor Geopolitical Developments: Establish a dedicated task force to monitor international events that could impact supply chains and proactively adjust sourcing and logistics strategies.

• Collaborate with Regulatory Bodies: Engage with international regulatory agencies to ensure compliance and to stay informed about potential regulatory changes that could affect supply chain operations.

RISK_LEVEL: MEDIUM